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Abstract
Background Diroximel fumarate (DRF) is a novel oral fumarate approved in the USA for relapsing forms of multiple sclerosis. DRF is converted to monomethyl fumarate, the pharmacologically active metabolite of dimethyl fumarate (DMF).
DRF 462 mg and DMF 240 mg produce bioequivalent exposure of monomethyl fumarate and are therefore expected to have
similar efficacy/safety profiles; the distinct chemical structure of DRF may contribute to its tolerability profile.
Objectives The objective of this study was to compare the gastrointestinal tolerability of DRF and DMF over 5 weeks in
patients with relapsing–remitting multiple sclerosis.
Methods EVOLVE-MS-2 was a phase III, randomized, double-blind, head-to-head, 5-week study evaluating the gastrointestinal tolerability of DRF 462 mg vs DMF 240 mg, administered twice daily in patients with relapsing–remitting multiple
sclerosis, using two self-administered gastrointestinal symptom scales: Individual Gastrointestinal Symptom and Impact
Scale (IGISIS) and Global Gastrointestinal Symptom and Impact Scale (GGISIS). The primary endpoint was the number of
days with an IGISIS intensity score ≥ 2 relative to exposure. Other endpoints included the degree of gastrointestinal symptom
severity measured by IGISIS/GGISIS and assessment of safety/tolerability.
Results DRF-treated patients experienced a statistically significant reduction (46%) in the number of days with an IGISIS
symptom intensity score ≥ 2 compared with DMF-treated patients (rate ratio [95% confidence interval]: 0.54 [0.39–0.75];
p = 0.0003). Lower rates of gastrointestinal adverse events (including diarrhea, nausea, vomiting, and abdominal pain) were
observed with DRF than DMF (34.8% vs 49.0%). Fewer patients discontinued DRF than DMF because of adverse events
(1.6% vs 5.6%) and gastrointestinal adverse events (0.8% vs 4.8%).
Conclusions DRF demonstrated an improved gastrointestinal tolerability profile compared with DMF, with less severe
gastrointestinal events and fewer days of self-assessed gastrointestinal symptoms, fewer gastrointestinal adverse events, and
lower discontinuation rates because of gastrointestinal adverse events.
Clinical Trials Registration ClinicalTrials.gov (NCT03093324).
Maria Lopez-Bresnahan and David Rezendes: Employees of
Alkermes Inc. during the time the research and analyses were
conducted.
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Electronic supplementary material The online version of this
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Extended author information available on the last page of the article

1 Introduction
Diroximel fumarate (DRF) is a novel oral fumarate
approved in the USA for the treatment of patients with
relapsing forms of multiple sclerosis (MS) [1]. DRF undergoes esterase cleavage to monomethyl fumarate, the same
pharmacologically active metabolite as the approved drug
Tecfidera® (delayed-release dimethyl fumarate [DMF]) [2].
When administered orally at doses of 462 mg and 240 mg,
respectively, DRF and DMF yield bioequivalent exposure

Vol.:(0123456789)

186

Key Points
EVOLVE-MS-2 was a 5-week head-to-head study
evaluating the gastrointestinal tolerability of diroximel
fumarate (DRF) vs dimethyl fumarate (DMF) in patients
with relapsing–remitting multiple sclerosis.
DRF-treated patients reported less severe gastrointestinal
events lasting fewer days compared with patients treated
with DMF.
Patients treated with DRF had lower rates of treatment
discontinuation due to gastrointestinal adverse events
than patients treated with DMF.
of monomethyl fumarate and therefore are expected to have
similar efficacy and safety profiles [3]. DMF has demonstrated significant and clinically meaningful efficacy, and a
well-tolerated safety profile in clinical trials and real-world
studies, totaling > 810,000 patient-years of exposure [4–8].
Gastrointestinal (GI) adverse events (AEs) such as nausea,
vomiting, abdominal pain, and diarrhea are not uncommon
with DMF, particularly in the first month of treatment [4, 5,
9]. In the pivotal DEFINE/CONFIRM trials (n = 1540), the
incidence of GI AEs was 40% and led to treatment discontinuation in 4% of patients [2, 10]. In a real-world study, up to
88% of patients treated with DMF reported GI events when
self-assessing GI symptoms using eDiaries [9]. Although
GI symptom management and mitigation approaches have
been developed, DMF treatment discontinuation because of
GI AEs still occurs and varies between 5 and 19% in realworld studies [11, 12].
The distinct chemical structure of DRF is hypothesized
to elicit less irritation in the GI tract than DMF through
lower production of methanol (a GI-irritating promoiety),
and less reactivity with pre-systemic off-target proteins or
receptors [13]. Interim findings from the ongoing, multicenter, 2-year, prospective, single-arm, open-label DRF
phase III EVOLVE-MS-1 study have demonstrated a low
rate (~ 31%) of GI AEs when considered within the context
of those reported in separate clinical trials and real-world
effectiveness studies of DMF [9, 10, 14]. Notably, < 1% of
patients in the EVOLVE-MS-1 study discontinued DRF
treatment because of GI AEs [14]. However, it is challenging to make any conclusions about differences in the GI tolerability profile between DRF and DMF in the absence of
head-to-head data.
Herein, we present final study results from the EVOLVEMS-2 study, which was designed to compare GI tolerability of DRF with DMF over 5 weeks in adults with relapsing–remitting MS (RRMS). The EVOLVE-MS-2 study
objectives were to (1) evaluate the utility of two GI symptom
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scales (Individual Gastrointestinal Symptom and Impact
Scale [IGISIS] and Global Gastrointestinal Symptom and
Impact Scale [GGISIS]); (2) compare GI tolerability of DRF
with DMF using these two GI symptom scales; and (3) evaluate the overall safety and tolerability of DRF, including
the incidence of GI AEs and number of study withdrawals
because of GI AEs in adults with RRMS.

2 Methods
2.1 Study Design
EVOLVE-MS-2 (NCT03093324) was a 5-week, randomized, double-blind, head-to-head, phase III study
designed to evaluate GI tolerability of DRF 462 mg vs DMF
240 mg administered twice daily in patients with RRMS.
Patients utilized two eDiary symptom scales to evaluate the
duration and severity of GI symptoms on a daily basis: IGISIS and GGISIS. In addition, AEs were collected by investigators at weekly study visits. The study included a ≤ 4-week
screening period, a 5-week double-blind treatment period
with two blinded treatment groups, and a 2-week followup period (Fig. 1). The screening period included a 1-week
lead-in period, prior to randomization, during which patients
completed the two self-administered GI symptom scales
daily to test for eDiary compliance and/or underlying baseline GI symptoms.
Block randomization was performed using a block size
of 4. Patients were randomized 1:1 into one of the two treatment groups, and all patients received two capsules twice
daily for all doses to maintain blinding. Patients received
either DRF at the approved dose of 231 mg twice daily
(administered as one 231-mg capsule and one placebo capsule twice daily) for week 1 followed by DRF 462 mg twice
daily (administered as two 231-mg capsules twice daily)
for weeks 2–5 (group 1), or DMF at the approved dose of
120 mg twice daily (administered as one 120-mg capsule
and one placebo capsule twice daily) for week 1 followed
by DMF 240 mg twice daily (administered as one 240-mg
capsule and one placebo capsule twice daily) for weeks 2–5
(group 2). The treatment period was double-blind; DMF
capsules were over-encapsulated to create the blinded study
drug. Patients were instructed to take the study drug with or
without food, but to avoid a high-fat and high-calorie meal
(defined as > 1000 calories and containing 50 g of fat) to
ensure adequate levels of monomethyl fumarate [2, 3]. No
dose reductions were permitted during the study. Symptomatic therapies for tolerability events were permitted and
recorded as concomitant medications.
The study utilized an adaptive study design, an approach
that allows for planned modifications to ongoing trials (such
as changes to trial parameters or statistical procedures) using
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pre-specified interim data analyses, without compromising
trial integrity or validity [15, 16]. Adaptive trial design has
been used to re-estimate sample size in instances in which
variances of the response variables are unknown, as was
the case with the novel endpoints used in the EVOLVEMS-2 study [17]. In this study, it was initially hypothesized
that comparing DRF and DMF using the IGISIS intensity
scale would detect a difference between the two groups.
As there was no previous experience with the IGISIS and
GGISIS scales to inform statistical assumptions, a preplanned unblinded analysis of data was conducted after the
first 120 patients were randomized (i.e., part A), in which
the objectives were to assess the utility of the GI symptom
scales; refine the primary endpoint to select the most sensitive measure for detecting a difference between DRF and
DMF; and inform the sample size. From this analysis, the
IGISIS endpoint was modified from ≥ 3 to ≥ 2 as the latter
was deemed to be the more sensitive indicator. All patients,
investigators, and sites remained blinded to the part A data
to preserve the integrity of the trial. After the initial 120
patients, the subsequently randomized patients (i.e., part B)
were enrolled, bringing the overall planned population to
500 patients. Patients who completed the 5-week treatment
period were eligible to enroll in the EVOLVE-MS-1 (ClinicalTrials.gov [NCT02634307]) long-term, open-label, DRF
safety study [14].

2.2 Patients
Eligible patients were aged 18–65 years, had a confirmed
diagnosis of RRMS [18], and were neurologically stable with no evidence of relapse in the 30 days prior to
screening. Patients were not eligible to participate if they
had a history of GI surgery (except appendectomy that

occurred > 6 months prior to screening); clinically significant recurring or active GI symptoms within 3 months of
screening or long-term use of medical therapy to treat GI
symptoms within 1 month of screening; or two or more
IGISIS intensity scores of ≥ 3 during the 1-week lead-in
period prior to randomization. Patients who had previously
received fumarate treatment were also prohibited from study
enrollment. The study was approved by central and local
ethics committees and was conducted in accordance with
the International Council on Harmonisation Guidelines for
Good Clinical Practice and the Declaration of Helsinki. All
patients provided written informed consent.

2.3 Study Endpoints
The primary endpoint was the number of days, relative to
exposure, with any IGISIS intensity score ≥ 2 in the overall
study population. Secondary endpoints included the number
of days, relative to exposure, with: (1) an IGISIS intensity
score ≥ 2 in part B only; (2) an IGISIS intensity score ≥ 1
in the overall population; (3) an IGISIS intensity score ≥ 3
in the overall population; (4) a GGISIS symptom intensity
score ≥ 1 in the overall population; (5) a GGISIS symptom
intensity score ≥ 2 in the overall population; (6) a GGISIS
symptom intensity score ≥ 3 in the overall population; and
(7) worst (i.e., highest) IGISIS individual symptom intensity
score by week during the 5-week treatment period in the
overall population.
Pre-specified exploratory endpoints included the number
of days relative to exposure with an IGISIS intensity score
of ≥ 1 and ≥ 3, or a GGISIS intensity score of ≥ 1, ≥ 2, or ≥ 3,
in part B only. Investigator-assessed AEs were summarized.

Treatment period
(5 weeks)

Follow-up
(2 weeks)

DRF 231 mg BID (Week 1); 462 mg BID (Weeks 2 – 5)
Screening

1:1
DMF 120 mg BID (Week 1); 240 mg BID (Weeks 2 – 5)

1
Week –4

2
3
Week –1
Week 1
Lead-in Randomization

4

5

6

7

8
Week 6
End of treatment

Patients who complete
EVOLVE-MS-2 may
roll over into the
96-week open-label
EVOLVE-MS-1 study

9
Week 8

Study visit

Fig. 1  EVOLVE-MS-2 study design. EVOLVE-MS-2 utilized an
adaptive study design and was conducted in two parts (A and B).
Parts A and B had an identical study design. The first 120 patients

randomized were included in part A and subsequent patients were
included in part B. BID twice daily dosing, DMF dimethyl fumarate,
DRF diroximel fumarate
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2.4 Assessments
2.4.1 Tolerability Assessments
Gastrointestinal tolerability was assessed using two novel
GI symptom scales, IGISIS and GGISIS. The scales were
adapted from the Modified Acute Gastrointestinal Symptom
Scale (MAGISS) and the Modified Overall Gastrointestinal
Symptom Scale (MOGISS) used in trials with DMF, which
have been previously described [9, 19]. The IGISIS is a
questionnaire designed to capture the incidence, intensity,
onset, duration, and functional impact of five key individual GI symptoms: nausea, vomiting, upper abdominal pain,
lower abdominal pain, and diarrhea (Fig. S1a in the Electronic Supplementary Material [ESM]). In the DMF pivotal
DEFINE/CONFIRM trials, these specific GI symptoms were
among the most commonly reported AEs and were the most
common GI AEs leading to treatment discontinuation [4, 5,
20]. Patients were instructed to self-administer the IGISIS
questionnaire twice per day within 9 h of taking the study
drug, using an eDiary. The patient rated the severity of each
symptom on a scale of 0 (did not have) to 10 (extreme);
for each symptom, patients also recorded duration and rated
interference on daily activities using a 5-point Likert scale
(Fig. S1a in the ESM).
The GGISIS is designed to assess the overall intensity of
five GI symptoms (nausea, vomiting, upper abdominal pain,
lower abdominal pain, and diarrhea) experienced during the
previous 24 h, the level of interference and functional impact
on work and daily activities, and how bothersome GI symptoms were for patients. To rate the intensity of GI symptoms
and assess how bothersome GI symptoms were, patients
completed the questionnaire once per day using a scale of
0 (did not have) to 10 (extreme). Patients also recorded the
level of interference and impact of GI symptoms on daily
activities and work (Fig. S1b in the ESM).
2.4.2 Safety Assessments
Safety assessments included AEs (including GI AEs), vital
signs, clinical laboratory tests (chemistry, hematology,
and urinalysis), and electrocardiogram findings. Adverse
events were assessed by the investigator at weekly visits and
recorded by severity and relatedness.

2.5 Analysis Populations and Statistics
Gastrointestinal tolerability was assessed in all patients who
received at least one dose of the study drug and completed at
least one post-baseline GI tolerability assessment. Data collected from patients in the overall population were analyzed
for the primary endpoint; secondary endpoints assessed data
from the overall population, as well as for part B separately.
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Based on the pre-planned unblinded analysis of the first
120 patients (part A data), it was assumed that the number of days with an IGISIS intensity score of ≥ 2 relative to
exposure in the treatment period would be 2.0 days for DRF
and 3.5 days for DMF. Using a negative binomial regression approach with a two-sided α-level of 0.05, it was estimated that an enrollment size of 500 total patients would
provide ~ 80% power to detect a ≥ 42% reduction in the relative rate for DRF vs DMF. The number of days with any
IGISIS individual symptom intensity score relative to exposure days was analyzed using a negative binomial regression
model with treatment as a factor and adjusted for study parts,
region, age, and body mass index. The worst IGISIS individual symptom intensity score during the treatment period
was summarized by treatment group and analyzed using
an analysis of covariance model with treatment as a factor
and adjusted for study parts, region, age, and body mass
index. Safety analyses were summarized for all patients who
received at least one dose of the study drug.

3 Results
3.1 Patients
A total of 854 patients underwent screening; 506 patients
were randomized and 504 patients received at least one dose
of the study drug (Fig. S2 in the ESM). Baseline demographics and disease characteristics were generally well balanced.
Approximately 50% of patients were enrolled from the
USA (Table 1). Most patients completed the study (94.8%,
478/504), 97.1% (464/478) of whom rolled over into the
EVOLVE-MS-1 study. The rate of discontinuation was lower
for patients treated with DRF compared with DMF (3.2% vs
7.2%, respectively). This difference in rate of discontinuation was predominantly attributable to the difference in the
rate of AEs leading to discontinuation (1.6% for DRF-treated
patients compared with 5.6% for DMF-treated patients).
Other reasons for discontinuation were similar between the
two groups (Table 2).
For the analysis of self-assessed GI events, 502 patients
were eligible for inclusion in the analysis; 253 were assigned
to DRF and 249 were assigned to DMF. For the IGISIS analyses, mean (standard deviation [SD]) exposure days were
comparable for the two groups: 35.2 (4.2) days for DRFtreated patients and 34.2 (5.9) days for DMF-treated patients.
When analyzing the part B population separately, 194 DRFtreated and 191 DMF-treated patients were included. Mean
(SD) exposure in the part B population was similar to that
of the overall population: 35.2 (3.8) days for DRF and 33.7
(6.3) days for DMF. For the GGISIS analyses, mean (SD)
exposure days with at least one diary available for analysis
were lower than that observed with IGISIS, yet comparable
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between the two groups: 33.3 (4.8) days for DRF and 32.6
(5.6) days for DMF.

3.2 Patient Self‑Assessed Gastrointestinal
Tolerability
The number of days with an IGISIS intensity score of ≥ 2
relative to exposure was statistically significantly lower with
DRF compared with DMF. The adjusted mean (95% confidence interval [CI]) number of days with a patient-assessed
event was 1.4 (1.1‒1.9) days with DRF and 2.6 (2.0‒3.3)
days with DMF. The adjusted rate ratio (95% CI) was 0.54
(0.39–0.75), representing a 46% reduction (p = 0.0003;
Fig. 2). A sensitivity analysis was performed to include only
diaries completed as instructed (within 2–9 h of dosing). The
mean (SD) number of evaluable days with diaries completed
as instructed were similar for the two groups: 25.8 (11.8) for
DRF and 26.1 (11.0) for DMF. Among diaries completed as
instructed, the adjusted mean (95% CI) number of days with
an IGISIS score of ≥ 2 relative to exposure was 1.0 (0.8‒1.3)
for DRF and 2.1 (1.6‒2.9) for DMF, resulting in an adjusted
rate ratio (95% CI) of 0.49 (0.34–0.70); this represented a
51% reduction (p < 0.0001).
When symptom intensity and frequency was assessed
using a GGISIS intensity score of ≥ 2, there were fewer days
of events with DRF compared with DMF, although the difference was not statistically significant. Patients treated with
DRF reported 1.1 (0.8‒1.5) adjusted mean (95% CI) days
with a GGISIS score of ≥ 2 compared with 1.6 (1.1‒2.2)
days for DMF-treated patients in the overall population. The
adjusted rate ratio (95% CI) was 0.67 (0.43–1.05; p = 0.082;
Fig. 2).
In a comparison using an IGISIS intensity score of ≥ 1,
the adjusted mean (95% CI) number of days relative to
exposure was significantly lower with DRF (3.0 [2.5‒3.7])
compared with DMF (4.1 [3.4‒5.0]). The rate ratio (95%
CI) was 0.71 (0.55–0.92), representing a 29% reduction
(p = 0.009; Fig. 2). The number of days relative to exposure with an IGISIS intensity score of ≥ 3 was 44% lower
with DRF than DMF (rate ratio [95% CI]: 0.56 [0.36‒0.86];
p = 0.009). Similarly, there were fewer days with a GGISIS
intensity score of ≥ 1 (rate ratio [95% CI]: 0.70 [0.50–0.98])
and ≥ 3 (0.74 [0.43–1.28]) with DRF than DMF over the
study period (Fig. 2).
In an analysis of data collected from part B only, the number of days with an IGISIS intensity score of ≥ 2 relative to
exposure was statistically significantly lower with DRF compared with DMF. The adjusted mean (95% CI) number of
days with a patient-assessed event for DRF-treated patients
was 1.2 (0.9‒1.5) days compared with 2.1 (1.7‒2.8) days for
DMF-treated patients. The adjusted rate ratio (95% CI) was
0.52 (0.36–0.76), representing a 48% reduction (p = 0.0007;
Fig. 3). Reductions consistent with those observed in the

Table 1  Baseline demographics and disease characteristics in
EVOLVE-MS-2

Mean (SD) age, years
Female, n (%)
Race, n (%)
White
Black or African American
Other
Mean (SD) weight, kg
Mean (SD) BMI, kg/m2
US region, n (%)
Prior DMT, n (%)
0
1
2
≥3
Mean (SD) time since diagnosis, years
Mean (SD) time since first symptom,
years
Mean (SD) no. of relapses in previous
year
Mean (SD) EDSS score
Mean (SD) no. of Gd + lesionsa
Patients with 0 Gd + lesions, n (%)

DRF
n = 253

DMF
n = 251

43.7 (10.96)
177 (70.0)

43.7 (9.90)
190 (75.7)

232 (91.7)
20 (7.9)
1 (0.4)
78.0 (18.7)
27.2 (5.9)
135 (53.4)

227 (90.4)
20 (8.0)
4 (1.6)
78.2 (19.6)
27.5 (6.1)
143 (57.0)

84 (33.2)
73 (28.9)
60 (23.7)
36 (14.2)
7.4 (7.80)
9.6 (8.96)

85 (33.9)
72 (28.7)
43 (17.1)
51 (20.3)
7.9 (7.37)
10.1 (8.55)

0.6 (0.72)

0.6 (0.72)

2.70 (1.407) 2.72 (1.380)
0.9 (2.22)
1.1 (2.76)
180 (71.1)
175 (69.7)

BMI body mass index, DMF dimethyl fumarate, DMT disease-modifying therapy, DRF diroximel fumarate, EDSS Expanded Disability
Status Scale, Gd + gadolinium-enhancing, SD standard deviation
a

DRF, n = 251; DMF, n = 251

overall population were also noted when comparing DRF
and DMF using IGISIS intensity scores of ≥ 1 (p = 0.01)
and ≥ 3 (p = 0.012) and GGISIS intensity scores of ≥ 1
(p = 0.028), ≥ 2, and ≥ 3 in the part B-only population (Fig.
S3 in the ESM).
Symptom severity was assessed using data collected from
the IGISIS eDiary. Over the course of the 5-week treatment
period, patients recorded an overall least squares (LS) mean
(standard error [SE]) worst IGISIS symptom intensity score
of 2.0 (0.2) if treated with DRF and 2.4 (0.2) if treated with
DMF (p = 0.069; Fig. 4). During the 1-week titration period,
LS mean (SE) worst symptom score was 1.0 (0.1) for DRF
vs 0.8 (0.1) for DMF. However, following the titration
period, LS mean (SE) worst symptom intensity score peaked
after the first week of the full-dose study drug for DMFtreated patients (DMF week 3, 1.4 [0.1]), before declining
by the end of treatment (DMF week 5, 0.6 [0.1]). In contrast,
DRF-treated patients experienced a gradual decline in LS
mean (SE) worst symptom score over the course of treatment (DRF week 3, 0.9 [0.1]; week 5, 0.5 [0.1]). Statistically
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Table 2  Disposition of patients
Patients, n (%)

Treatment group

Randomized
Received at least one dose of the study drug
Completed the treatment period
Completed the s tudya
Rolled over to EVOLVE-MS-1
Discontinued during the study period
Adverse events
Lost to follow-up
Protocol deviation
Withdrawal by patient
Lack of efficacy
Physician decision
Other

DRF

DMF

254 (100)
253 (99.6)
245 (96.8)
245 (96.8)
239 (94.5)
8 (3.2)
4 (1.6)
1 (0.4)
1 (0.4)
2 (0.8)
0
0
0

252 (100)
251 (99.6)
233 (92.8)
233 (92.8)
225 (89.6)
18 (7.2)
15 (6.0)
0
1 (0.4)
2 (0.8)
0
0
0

DMF dimethyl fumarate, DRF diroximel fumarate
a

End of study included completion of the treatment period in patients
rolling over into the EVOLVE-MS-1 trial, and completion of the
treatment period and the 2-week follow-up period in patients who did
not roll over into the EVOLVE-MS-1 trial

6
of days relative to exposure

Adjusted mean (95% CI) total number

significant differences with DRF vs DMF were observed
in week 3 (DRF: 0.9 [0.1] vs DMF: 1.4 [0.1], p = 0.002)
and week 4 (DRF: 0.6 [0.1] vs DMF: 1.0 [0.1], p = 0.004).
The IGISIS worst symptom intensity scores were lower with
DRF than DMF for events associated with the upper GI tract

(with statistically significant reductions observed for nausea,
vomiting, upper abdominal pain) but similar for events associated with the lower GI tract (diarrhea, lower abdominal
pain; Table 3).
Fewer patients treated with DRF categorized their GI
events as interfering “quite a bit” or “extremely” with the
ability to accomplish daily activities when assessed using
both IGISIS and GGISIS scales, compared with patients
treated with DMF: nausea (2.4% vs 6.8%), vomiting (1.2%
vs 5.6%), upper abdominal pain (1.2% vs 6.8%), lower
abdominal pain (1.2% vs 3.2%), diarrhea (3.6% vs 6.4%),
and all GI events (GGISIS, 7.9% vs 10.8%; Table S1 in the
ESM). In addition, a higher percentage of patients treated
with DRF assessed the impact of their GI events as “not
at all” affecting work productivity (47.8%, 121/253) compared with DMF (40.6%, 101/249), and for those reporting
employment and missed hours at work because of GI events
(DRF, 20/133; DMF, 26/133) the mean (SD) greatest number of hours missed was lower for patients treated with DRF
than DMF: 4.3 (3.7) and 5.5 (4.8), respectively.

3.3 Safety
Overall, AEs were reported in 81% (408/504) of patients
(DRF, 78.3%; DMF, 83.7%; Table 4). Most AEs were mild
to moderate in severity (DRF, 97.5% [193/198]; DMF,
93.3% [196/210]; Table 4). The overall rate of serious AEs
was low (1.4%; four patients with DRF and three patients
with DMF); none were related to the study drug. No deaths

RR (95% CI):
0.71 (0.55–0.92)
p = 0.009
RR (95% CI):
0.70 (0.50–0.98)
p = 0.036

RR (95% CI):
0.54 (0.39–0.75)
p = 0.0003

RR (95% CI):
0.67 (0.43–1.05)
p = 0.082

RR (95% CI):
0.56 (0.36–0.86)
p = 0.009

4

DMF
DRF

RR (95% CI):
0.74 (0.43–1.28)
p = 0.281

2

0
IGISIS ≥ 1

IGISIS ≥ 2
Primary endpoint

IGISIS ≥ 3

GGISIS ≥ 1

GGISIS ≥ 2

GGISIS ≥ 3

Gastrointestinal symptom intensity score

Fig. 2  Primary and secondary endpoints in the overall population.
For the overall population: diroximel fumarate (DRF), n = 253; dimethyl fumarate (DMF), n = 249. CI confidence interval, GGISIS Global

Gastrointestinal Symptom and Impact Scale, IGISIS Individual Gastrointestinal Symptom and Impact Scale, RR rate ratio
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specifically designed to assess the duration and severity of
key GI events: nausea, vomiting, diarrhea, and upper and
lower abdominal pain.
EVOLVE-MS-2 is the first study to directly compare
the GI tolerability profiles of two MS treatments. Patients
treated with DRF reported significantly fewer days with GI
events, with an IGISIS severity score of ≥ 2 over a 5-week
period, than patients treated with DMF. This finding, which
favored DRF, was consistently observed across comparisons
using different severity score thresholds on both IGISIS and
GGISIS. The observed differences in days with GI events
and severity of GI events as assessed by the patient were
supported by lower rates of investigator-assessed GI AEs and
GI AEs leading to treatment discontinuation in DRF-treated
patients. In addition, patients treated with DRF tended to
report that GI events were less likely to interfere with their
daily activities, less bothersome, and less likely to impact
work productivity and absenteeism. Although the absolute
difference in number of days with GI events with DRF and
DMF as measured by IGISIS was small, the improvements
observed with DRF support clinically meaningful and relevant outcomes such as fewer treatment discontinuations,
less patient-reported interference of GI symptoms, and
fewer effects on work productivity. The timing of treatment
benefit is also important. Most (91.7%; 11/12) DMF treatment discontinuations in EVOLVE-MS-2 occurred by week
3. Therefore, although worst GI symptom severity scores
with DRF and DMF tend to be similar by week 5 (Fig. 4),
the early differences observed by week 3 appear to provide
meaningful patient benefit.

were reported. Gastrointestinal AEs were among the most
frequently reported; 34.8% in the DRF treatment group and
49.0% in the DMF treatment group. In particular, GI AEs
associated with an upper GI location (upper abdominal
pain, nausea, vomiting) appeared to be reported with less
frequency in patients treated with DRF compared with DMF
(Table 5). Overall, 19.3% (17/88) of patients in the DRF
group and 30.6% (37/121) of patients in the DMF group
used concomitant medications to treat GI-related AEs during
the treatment period. Two patients in the DMF group experienced a GI AE that was not considered tolerability related
(toothache, n = 1; dry mouth, n = 1) and were excluded from
the analysis. Flushing was reported in 36.7% of patients
overall (DRF, 32.8%; DMF, 40.6%).
The incidence of AEs leading to treatment discontinuation was lower for patients treated with DRF (1.6%) compared with DMF (5.6%). Gastrointestinal AEs led to discontinuation in 0.8% of patients treated with DRF and 4.8% of
patients treated with DMF. No patients in either treatment
group discontinued because of lack of efficacy.

4 Discussion
Results from the EVOLVE-MS-2 study demonstrate that
DRF has an improved GI tolerability profile compared with
DMF. Tolerability is an important factor for drug adherence
and achievement of maximal efficacy, particularly for medications used for long-term management of chronic diseases
such as MS [21]. This randomized double-blind study was

DMF
DRF

3
of days relative to exposure

Adjusted mean (95% CI) total number

RR (95% CI):
0.52 (0.36–0.76)
p = 0.0007

2

1

0
DMF

DRF

IGISIS intensity score ≥ 2

Fig. 3  Number of days relative to exposure with an Individual Gastrointestinal Symptom and Impact Scale (IGISIS) intensity score ≥ 2
for diroximel fumarate (DRF) vs dimethyl fumarate (DMF) in

patients enrolled after the pre-planned analysis of the first 120
patients (part B only). For part B only: DRF, n = 194; DMF, n = 191.
CI confidence interval, RR rate ratio
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DRF
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worst severity scorea

Adjusted mean (SE) weekly

p = 0.002
1.5

p = 0.441
p = 0.219

p = 0.004

1.0
p = 0.288
0.5

0.0
1

2

3

4

5

246
233

245
232

Study week
DRF, n
DMF, n

250
247

252
249

249
242

Fig. 4  Mean worst severity score for gastrointestinal events (Individual Gastrointestinal Symptom and Impact Scale [IGISIS]) by
weekly interval in the overall population. DMF dimethyl fumarate,

DRF diroximel fumarate, SE standard error. aAnalysis of covariance
model; factors include study parts, region (USA and non-USA), age,
and body mass index

Table 3  Individual Gastrointestinal Symptom and Impact Scale (IGISIS) worst individual symptom intensity score by gastrointestinal
(GI) location reported during the 5-week treatment period

Table 4  On-treatment safety summary

IGISIS worst individual symptom
intensity score
Upper GI events
Upper abdominal pain
LS mean (SE)a
P value
Nausea
LS mean (SE)a
P value
Vomiting
LS mean (SE)a
P value
Lower GI events
Lower abdominal pain
LS mean (SE)a
P value
Diarrhea
LS mean (SE)a
P value

DRF
n = 253

DMF
n = 249

0.8 (0.1)
0.001

1.3 (0.1)

1.0 (0.1)
0.043

1.3 (0.1)

0.2 (0.1)
< 0.001

0.7 (0.1)

0.9 (0.1)
0.403

1.0 (0.1)

1.1 (0.1)
0.261

1.4 (0.2)

DMF dimethyl fumarate, DRF diroximel fumarate, LS least squares,
SE standard error
a

LS mean symptom intensity score was analyzed using an analysis of
covariance model adjusted for study parts, region (USA vs non-USA),
age, and body mass index

For DRF, fewer upper GI events (nausea, vomiting, upper
abdominal pain) were reported when assessed by patients
and investigators, which is consistent with the hypothesis
that DRF may potentially elicit less localized GI irritation

TEAE, n (%)

DRF
n = 253

DMF
n = 251

Any TEAE
Mild
Moderate
Severe
Serious AEa
AE leading to d iscontinuationb
GI AE leading to discontinuation
Upper abdominal pain
Diarrhea
Abdominal pain
Vomiting
Abdominal distension
GI pain
Nausea

198 (78.3)
125 (49.4)
68 (26.9)
5 (2.0)
4 (1.6)
4 (1.6)
2 (0.8)
0
1 (0.4)
0
1 (0.4)
0
0
0

210 (83.7)
121 (48.2)
75 (29.9)
14 (5.6)
3 (1.2)
14 (5.6)c
12 (4.8)
5 (2)
3 (1.2)
3 (1.2)
2 (0.8)
1 (0.4)
1 (0.4)
1 (0.4)

AE adverse event, DMF dimethyl fumarate, DRF diroximel fumarate,
GI gastrointestinal, TEAE treatment-emergent adverse event
a

Serious AEs in DRF-treated patients included: multiple sclerosis relapse, n = 2; multiple sclerosis relapse and suicide attempt,
n = 1; atrial fibrillation, n = 1. Serious AEs in DMF-treated patients
included: multiple sclerosis relapse, n = 2; cholecystitis, n = 1

b

AEs leading to DRF treatment discontinuation were GI AEs (n = 2,
listed in table), dermatitis allergic (n = 1), and suicide attempt (n = 1).
AEs leading to DMF treatment discontinuation were GI AEs (n = 12,
listed in table), depression (n = 1), and urticaria (n = 1)

c

One patient in the DMF arm reported an AE after the last study-dose
date (post-treatment period, during the follow-up period) that led to
discontinuation from the study. This patient is captured as having an
AE leading to discontinuation from the study (Table 2) but not as
having an AE leading to discontinuation during the treatment period
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compared with DMF, owing to its distinct chemical structure
[13]. The potential impact would likely be most evident in
the upper GI tract, given that both DRF and DMF are formulated to be released from their capsules and microspheres
upon traversing from the stomach into the small intestine;
this region of the GI tract would be exposed to the highest
concentrations of DRF and DMF, allowing for greater differentiation of their tolerability effects. This was reflected in
the worst symptom intensity scores (IGISIS), which show
statistically significant differences in favor of DRF for upper
GI tract symptoms.
The IGISIS and GGISIS scales were utilized for this
study to assess GI symptoms given that evaluation of GI
events is not a typical assessment for the management of
MS, and no validated scales are currently available to measure such outcomes. As there was no previous experience
with the IGISIS and GGISIS scales to inform statistical
assumptions, an adaptive trial design was used to enable
the selection of a sensitive primary endpoint and inform
statistical assumptions for the overall study (see Methods).
To mitigate the possibility of a type I error, an analysis to
validate the primary endpoint only in patients enrolled after
the unblinding (i.e., part B) was included. Results from the
part B-only analysis were aligned with that for the overall

population on the primary endpoint (46% reduction in the
total population; 48% reduction in the part B cohort) as well
as secondary endpoints.
Interestingly, the rates of investigator-assessed GI AEs
and discontinuations because of GI AEs reported for DRFand DMF-treated patients were consistent with rates in the
ongoing EVOLVE-MS-1 study, as well as with rates in the
pivotal DEFINE and CONFIRM studies, though the trials
cannot be directly compared [4, 5, 14]. The incidence of
flushing, though numerically lower with DRF than DMF in
this study, was generally consistent with rates reported in
phase III studies with DRF and DMF [4, 5, 14]. However, as
the focus of EVOLVE-MS-2 was GI tolerability, we did not
evaluate and cannot assess the impact of flushing on patients
in the study. There were no unexpected or new safety events,
including lymphopenia, reported for patients taking either
DRF or DMF, and the overall safety profile was consistent
with the known safety profile for each therapy, including
interim findings from the ongoing open-label EVOLVE-MS-1
study [14].
There were limitations of the study. There is potential
for bias toward over-reporting when patients self-assess GI
events in a study designed to measure GI tolerability using
eDiaries three times per day. In this setting, patients were

Table 5  Treatment-emergent adverse events (TEAEs) experienced in ≥ 5% of patients (in any group)
System organ class preferred term, n (%)

Any TEAE
Gastrointestinal disorders
Diarrhea
Nausea
Upper abdominal pain
Abdominal pain
Lower abdominal pain
Vomiting
General disorders and administration site conditions
Fatigue
Infections and infestations
Nasopharyngitis
Investigations
Alanine aminotransferase increased
Nervous system disorders
Headache
Skin and subcutaneous tissue disorders
Erythema
Pruritus
Vascular disorders
Flushing
DMF dimethyl fumarate, DRF diroximel fumarate

Treatment groups
DRF
(n = 253)

DMF
(n = 251)

198 (78.3)
88 (34.8)
39 (15.4)
37 (14.6)
17 (6.7)
16 (6.3)
15 (5.9)
9 (3.6)
16 (6.3)
6 (2.4)
43 (17.0)
15 (5.9)
27 (10.7)
14 (5.5)
37 (14.6)
10 (4.0)
49 (19.4)
20 (7.9)
18 (7.1)
88 (34.8)
83 (32.8)

210 (83.7)
123 (49.0)
56 (22.3)
52 (20.7)
39 (15.5)
24 (9.6)
17 (6.8)
22 (8.8)
30 (12.0)
13 (5.2)
35 (13.9)
11 (4.4)
24 (9.6)
9 (3.6)
34 (13.5)
14 (5.6)
58 (23.1)
21 (8.4)
18 (7.2)
107 (42.6)
102 (40.6)
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aware via their informed consent that they could potentially
receive an investigational product that would reduce GI
events, which may have conversely resulted in less reporting
overall. Owing to the prospective randomized blinded nature
of the study, no bias would have been introduced, although it
may have artificially lowered the overall magnitude of difference detected between both arms. The IGISIS and GGISIS
scales capture five GI symptoms (nausea, vomiting, upper
abdominal pain, lower abdominal pain, and diarrhea) that
were most commonly reported in the DEFINE and CONFIRM trials of DMF. However, patients in EVOLVE-MS-2
did experience GI AEs beyond the five included in the IGISIS/GGISIS assessments. Although the scales do not capture
every GI AE, the events that are not included occur at low
rates (incidence ≤ 2%). Additionally, the short duration of
treatment (5 weeks) limits the ability to determine the time
of resolution of AEs that were ongoing at the study end, and
prohibits the assessment of AEs that occur with a latency.
Hence, it does not fully describe the AE profile of DRF and
DMF, although this was not the intent of the study. Despite
this limited follow-up, the AE profile was consistent with
the known profiles for both DRF and DMF, and the high
percentage of patients rolling over into the EVOLVE-MS-1
study will allow for the evaluation of the DRF AE profile for
up to 2 years on treatment.

5 Conclusions
In this 5-week head-to-head study evaluating the GI tolerability of DRF vs DMF in patients with RRMS, DRF-treated
patients assessed their GI events as less severe and lasting
fewer days when compared with patients treated with DMF.
Importantly, rates of GI AEs and rates of discontinuation due
to GI AEs were lower for patients treated with DRF. Taken
together, these findings indicate that DRF has an improved
GI tolerability profile compared with DMF, which may lead
to better long-term adherence and persistence to therapy.
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